Rocket Pharmaceuticals, Inc.
A developer of gene therapies for rare, life-threatening genetic diseases, Rocket Pharmaceuticals works to correct the underlying genetic defects behind conditions like Danon disease and leukocyte adhesion deficiency. Founded in 2015 and merged with Inotek Pharmaceuticals in 2018, the company's name reflects its "moonshot" ambition to bring speed to medicine. Its therapies either modify a patient's own blood stem cells outside the body or deliver corrected genes directly via engineered viruses.
Granted 1.88M · Bought 1.02M · Sold 725.0K
Bought 1.36M
Granted 47.7K
Bought 814.2K
Bought 958.2K
Bought 603.8K
Bought 603.8K
Bought 416.7K
Bought 212.4K
Granted 9.9K
Granted 1.09M · Bought 42.0K · Sold 254.3K
Granted 363.5K · Bought 27.8K · Sold 47.6K
Granted 49.4K · Sold 344.1K
Granted 680.9K · Sold 48.7K
Granted 469.1K
Granted 407.9K
Granted 393.4K · Sold 172.2K
Granted 125.9K · Sold 17.6K
Granted 304.6K · Bought 60.0K · Sold 176.5K
Granted 137.1K · Sold 9.0K
Granted 130.8K · Sold 77.0K
Sold 637
Granted 87.8K · Sold 18.6K
Granted 54.7K
Granted 53.3K
Granted 30.0K · Bought 20.0K
Granted 30.0K
Granted 30.0K
Granted 30.0K
Granted 30.0K
Granted 12.5K
Bought 10.0K
Bought 814.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Wong Roderick +2 co-filersDirector, 10% owner · 8 transactions | — | 32.46Mas of Aug 2021 | 1.88M | 1.02M | 725.0K |
| Wong Roderick +1 co-filerDirector, 10% owner, See remarks, Director, 10% owner, See Remarks · 12 transactions | — | 18.30M | — | 1.36M | — |
| Wong RoderickDirector, 10% owner · 2 transactions | — | 18.24Mas of Jul 2025 | 47.7K | — | — |
| Kantesaria Devang10% owner · 3 transactions | — | 8.00Mas of Feb 2015 | — | 814.2K | — |
| Kairouz Habib +9 co-filers10% owner · 3 transactions | — | 6.86Mas of Feb 2015 | — | 958.2K | — |
| Karabelas Argeris NDirector, 10% owner · 3 transactions | — | 5.78Mas of Feb 2015 | — | 603.8K | — |
| Care Capital II LLC +5 co-filers10% owner · 3 transactions | — | 5.56Mas of Feb 2015 | — | 603.8K | — |
| MedImmune Ventures, Inc.10% owner · 3 transactions | — | 5.05Mas of Feb 2015 | — | 416.7K | — |
| Pitango G.C. Capital Holdings Ltd. +3 co-filers10% owner · 3 transactions | — | 3.61Mas of Feb 2015 | — | 212.4K | — |
| Kantesaria Devang +2 co-filers10% owner · 1 transaction | — | 3.25Mas of Jul 2015 | 9.9K | — | — |
| Shah GauravCEO · 57 transactions | — | 1.52M | 1.09M | 42.0K | 254.3K |
| Patel KinnariSee Remarks · 31 transactions | — | 1.12Mas of May 2025 | 363.5K | 27.8K | 47.6K |
| Makker GothamDirector · 9 transactions | — | 1.02Mas of Jul 2025 | 49.4K | — | 344.1K |
| Wilson MartinGeneral Counsel · 25 transactions | — | 678.0K | 680.9K | — | 48.7K |
| Rho Ventures IV Holdings LLC +1 co-filer10% owner · 2 transactions | — | 636.5Kas of Nov 2015 | — | — | — |
| Stevens Christopher JamesChief Operating Officer · 2 transactions | — | 469.1K | 469.1K | — | — |
| Rizvi Syed Ali-aamirChief Medical Officer · 3 transactions | — | 407.9K | 407.9K | — | — |
| Schwartz Jonathan DavidSee Remarks · 22 transactions | — | 299.1K | 393.4K | — | 172.2K |
| Chaudhuri SarbaniSee Remarks · 2 transactions | — | 267.5K | 125.9K | — | 17.6K |
| Southwell David PDirector · 14 transactions | — | 144.8Kas of Jul 2025 | 304.6K | 60.0K | 176.5K |
| Ondrey AaronChief Financial Officer · 4 transactions | — | 128.2Kas of Jul 2025 | 137.1K | — | 9.0K |
| Militello JohnSee Remarks · 51 transactions | — | 89.8K | 130.8K | — | 77.0K |
| Yalamanchi NaveenDirector · 2 transactions | — | 82.4Kas of Dec 2020 | — | — | 637 |
| White Mark AndrewSee Remarks · 5 transactions | — | 69.1Kas of Oct 2024 | 87.8K | — | 18.6K |
| Granadillo Pedro PDirector · 2 transactions | — | 54.7Kas of Jun 2025 | 54.7K | — | — |
| Fong PeterDirector · 2 transactions | — | 53.3K | 53.3K | — | — |
| Bjork ElisabethDirector · 3 transactions | — | 50.0K | 30.0K | 20.0K | — |
| Dolsten MikaelDirector · 2 transactions | — | 44.2Kas of Jun 2025 | 30.0K | — | — |
| Boess CarstenDirector · 1 transaction | — | 30.0Kas of Jun 2025 | 30.0K | — | — |
| Malik Fady IbrahamDirector · 1 transaction | — | 30.0Kas of Jun 2025 | 30.0K | — | — |
| Pratumsuwan PiratipDirector · 1 transaction | — | 30.0Kas of Jun 2025 | 30.0K | — | — |
| Ritter DaleVice President, Finance · 1 transaction | — | 19.8Kas of Sep 2017 | 12.5K | — | — |
| Carroll J MartinDirector · 1 transaction | — | 10.0Kas of May 2016 | — | 10.0K | — |
| Devon Park Bioventures LP +2 co-filers10% owner · 5 transactions | — | 9.9Kas of Jan 2017 | — | 814.2K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +5.07M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.